Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Janet R. Phelps"'
Autor:
Andrew G. Cole, Steven G. Kultgen, Nagraj Mani, Andrzej Ardzinski, Kristi Yi Fan, Emily P. Thi, Bruce D. Dorsey, Kim Stever, Tim Chiu, Sunny Tang, Owen Daly, Janet R. Phelps, Troy Harasym, Andrea Olland, Robert K. Suto, Michael J. Sofia
Publikováno v:
RSC Med Chem
Disruption of the HBV viral life cycle with small molecules that prevent the encapsidation of pregenomic RNA and viral polymerase through binding to HBV core protein is a clinically validated approach to inhibiting HBV viral replication. Herein we re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc3d746e0df2833c3377ff3c4df6151d
https://europepmc.org/articles/PMC8942244/
https://europepmc.org/articles/PMC8942244/
Autor:
Kristi Fan, Andrea Cuconati, Robbin Burns, Xiaowei Teng, Amy C.H. Lee, Nagraj Mani, Ellen Evangelista, Bruce D. Dorsey, Sunny Tang, Salam Kadhim, Roseann Kowalski, Angela Miller, Troy Harasym, Janet R. Phelps, Kim Stever, Andrzej Ardzinski, Alice H. Li, Chris Pasetka, Rene Rijnbrand, Andrew G. Cole, Holly M. Micolochick Steuer, Stephen P. Reid, Steven G. Kultgen, Michael J. Sofia, Xiaohe Wang, Tim T. Chiu, Sara A. Majeski, Fang Guo
Publikováno v:
Antiviral research. 197
AB-506, a small-molecule inhibitor targeting the HBV core protein, inhibits viral replication in vitro (HepAD38 cells: EC50 of 0.077 μM, CC50 > 25 μM) and in vivo (HBV mouse model: ∼3.0 log10 reductions in serum HBV DNA compared to the vehicle co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39029ab6adc8f539c39058419e8ea3e4
https://pubmed.ncbi.nlm.nih.gov/34826506
https://pubmed.ncbi.nlm.nih.gov/34826506
Autor:
Alice H. L. Li, Xiaohe Wang, Andrew S. Kondratowicz, Chris Pasetka, Janet R. Phelps, Michael J. Sofia, Nicholas M. Snead, Ammen P. Dhillon, Kaylyn Kwak, Andrzej Ardzinski, Kyle D. Cobarrubias, Xin Ye, Andrea Cuconati, Luying Pei, Angela Miller, Lale Bidirici-Ertekin, Amy C.H. Lee, Emily P. Thi
Publikováno v:
ACS infectious diseases. 5(5)
Current approved nucleoside analogue treatments for chronic hepatitis B virus (HBV) infection are effective at controlling viral titer but are not curative and have minimal impact on the production of viral proteins such as surface antigen (HBsAg), t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::284884f962cca651c5d79ac5cda2daa6
https://pubmed.ncbi.nlm.nih.gov/30403127
https://pubmed.ncbi.nlm.nih.gov/30403127
Autor:
Richeng Mao, Bruce D. Dorsey, Andrew G. Cole, Quanxin Long, Alice H. L. Li, Sunny Tang, Rene Rijnbrand, Troy Harasym, Ellen Evangelista, Xiaohe Wang, Nicholas M. Snead, Kevin McClintock, Sara A. Majeski, Haitao Guo, Nagraj Mani, Kyle D. Cobarrubias, Stephen P. Reid, Fang Guo, Holly M. Micolochick Steuer, Janet R. Phelps, Steven G. Kultgen, Andrea Cuconati, Ju-Tao Guo, Qiong Zhao, Amy C.H. Lee, Salam Kadhim, Kim Stever, Kristi Fan, Andrzej Ardzinski, Michael J. Sofia
Publikováno v:
Antimicrobial Agents and Chemotherapy. 62
AB-423 is a member of the sulfamoylbenzamide (SBA) class of hepatitis B virus (HBV) capsid inhibitors in phase 1 clinical trials. In cell culture models, AB-423 showed potent inhibition of HBV replication (50% effective concentration [EC 50 ] = 0.08
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eb13806874a26837c9f4e00e6bd6269
https://doi.org/10.1128/aac.00082-18
https://doi.org/10.1128/aac.00082-18
Autor:
Ian MacLachlan, Erik Z. Yu, Joan B. Geisbert, Adam Judge, Amy C.H. Lee, Lloyd Jeffs, Kathleen M. Daddario-DiCaprio, Janet R. Phelps, Elliott Kagan, Lisa E. Hensley, Kevin McClintock, Thomas W. Geisbert, Peter B. Jahrling, Elizabeth A. Fritz
Publikováno v:
The Journal of Infectious Diseases
Background. Ebola virus (EBOV) infection causes a frequently fatal hemorrhagic fever (HF) that is refractory to treatment with currently available antiviral therapeutics. RNA interference represents a powerful, naturally occurring biological strategy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::783f8229abf19a2e237a1d169d34fcc5
https://doi.org/10.1086/504267
https://doi.org/10.1086/504267
Publikováno v:
Molecular Therapy. 13:328-337
The systemic application of nucleic acid drugs requires delivery systems that overcome the poor pharmacokinetics, limited biodistribution, and inefficient uptake of nucleic acids. PEGylated liposomes show considerable promise because of their intrins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd1726aa259741508897d1391d234728
https://doi.org/10.1016/j.ymthe.2005.09.014
https://doi.org/10.1016/j.ymthe.2005.09.014